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Bone lead in dialysis patients. We measured lead and calcium in
multiple bone biopsies from II cadavers without known excessive past
exposure to lead. Paired iliac crest, transiliac and tibial bone biopsies
from these cadavers indicated that in bone biopsy specimens the
lead/calcium ratio is more reproducible than the absolute lead concen-
tration. There were no significant differences between the lead/calcium
ratios from the iliac crest, transiliac, or tibial specimens. Transiliac
bone biopsies from 35 patients (13 patients showing symptoms of slight
or moderate degree of renal failure, medical history of gout and/or
arterial hypertension and 22 lead workers with chelatable lead in excess
of 1000 g) indicated that the lead and the lead/calcium ratio in bone
biopsies reflect body lead stores as estimated by the EDTA test (r =
0.87 and 0.83, respectively). Chemical and histological studies of
transiliac biopsies previously obtained from 153 dialysis patients (from
8 dialysis centers from Belgium, France and Germany) for studies of
aluminum-induced bone disease showed that chronic renal failure and
dialysis do not cause accumulation of lead in bone and elevated bone
lead does not appear to alter trabecular bone histomorphometry. We
found that in 5% of the hemodialysis population studied, bone lead
concentrations approximated levels found in active lead workers.
Lead nephropathy has been suggested as a cause of renal
failure [1]. Diagnostic criteria for lead nephropathy, however,
remain controversial [2, 3]. The CaNa2EDTA lead mobilization
test has proven to be of value for detecting excessive past lead
exposure [4, 51. In gout patients and in hypertensive patients
with renal failure, chelation testing has helped to establish a
possible etiologic role for lead [4—8]. Over 90% of the body lead
is stored in bone [91 and it is believed that the EDTA test
reflects these stores [10]. However, the effect of renal failure on
bone lead concentrations and the value of bone biopsies for
establishing excessive lead accumulation have not been system-
atically examined.
When the EDTA test is used in the diagnosis of lead nephrop-
athy, it is assumed that chelatable lead is a reliable measure of
cumulative prior absorption. The conclusion that excessive lead
accumulation is the cause, rather than the consequence of renal
failure when other causes of renal disease have been excluded
is based in part upon the absence of increased chelatable lead in
control patients with comparable renal failure of known etiol-
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ogy unrelated to lead [4—7, 11—14]. This interpretation would be
invalid if the EDTA test would not reflect bone lead stores in all
subjects equally. If the ability to chelate lead from patients with
renal failure unrelated to lead is systematically less than from
gout and hypertensive patients with comparable renal failure,
increased chelatable lead could be interpreted as being due to
differences in bone lead availability for chelation rather than to
an increased body burden. This possibility has recently been
underlined by the observation that patients with lead-induced
gout nephropathy had significantly higher immunoreactive para-
thormone (iPTH) levels than did control glomerulonephritics
with comparable renal failure [61. These differences in iPTH
could induce differences in bone lead availability.
The objective of the study was threefold. In order to deter-
mine the reproducibility of measurements in bone biopsies from
different anatomical sites and to establish reference bone lead
values in unexposed individuals, multiple biopsies were ob-
tained from human cadavers. To determine if the EDTA lead
mobilization test is correlated with body lead stores, chelatable
lead was evaluated by lead measurements in bone biopsies from
patients including known lead workers. To study the relation
between lead and renal failure, lead was measured in transiliac
biopsy specimens from unselected chronic hemodialysis pa-
tients from several centers of different areas.
These studies provide reference lead values from which bone
lead levels can be defined for iliac (that is, ilia.. crest or
transiliac) bone biopsies and show that transiliac bone lead is
elevated in a non-negligible percentage of the studied dialysis
population.
Methods
Cadaver bone biopsies
Multiple bilateral bone biopsies were obtained at postmortem
examination from 11 subjects without and from one additional
cadaver with documented excessive exposure to lead. Six of
these were chronic dialysis patients and the others did not have
renal failure. In four of the cadavers, only transiliac biopsies
were obtained. In all cases left as well as right-sided biopsies
were taken and often multiple samples were collected on each
side. Iliac crest bone biopsies were obtained with a Vim-
Silverman needle (2 mm internal bore) and transiliac and tibial
biopsies were obtained with a Bordier-Meunier needle (7 mm
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internal bore). Transiliac bone biopsies were taken 2 cm poste-
nor and inferior of the anterior iliac spine. Tibia! cores were
obtained from the anterior medial aspect of the central mid-
diaphyseal region.
EDTA tests and transiliac biopsies
EDTA tests, transiliac bone biopsies were performed and
histories of lead exposure were investigated in 35 at risk
patients [slight or moderate degree of renal failure, medical
history of gout and/or arterial hypertension (N = 13) or lead
workers (N 22)1, after obtaining informed consent. The
EDTA test was performed by giving two injections of 1 g (5 ml)
CaNa2EDTA mixed with 1 ml 2% lidocaine by deep intramus-
cular injection 12 hours apart and collecting 24 hour urines for
one (patients with normal renal function) or three days (patients
with renal failure) following the first injection. Renal failure was
defined as creatinine clearance below the third percentile [15].
Baseline urines were collected over the 24 hours prior to the
EDTA test and a blood sample was taken on the same day.
Transiliac biopsies in dialysis patients
Transverse iliac biopsy specimens previously obtained from
153 chronic hemodialysis patients for studies of aluminum-
induced bone disease [16] were analyzed for lead and calcium.
Lead, calcium and aluminum measurements were performed in
the same nitric acid digested samples. Of the dialysis patients,
66 were Belgian, 59 German and 28 French. The studied
population was comparable according to age and sex with the
total patient group of two contributing centers. The patients
were entered into the aluminum study before analysis for lead
was considered. None had been suspected of having lead
nephropathy. The biopsies are therefore an unselected sample
of dialysis patients with respect to this lead study.
Bone analysis
The concentrations of lead and aluminum were determined in
bone biopsies by electrothermal atomic absorption spectrome-
try (Perkin Elmer, Model 372, HGA 500, Perkin Elmer,
Norwalk, Connecticut, USA) and calcium was determined by
flame atomic absorption spectrometry (Perkin Elmer, Model
372). Biopsy specimens were cleaned with a plastic disposable
scalpel to remove adherent soft tissue and immediately placed
in stoppered polystyrene tubes, weighed and stored at 4°C. For
determinations of lead and aluminum, specimens were trans-
ferred quantitatively to Teflon tubes or digestion bombs and
digested with nitric acid at 90°C for two to three hours [17].
Only aluminum- and lead-free materials were Used. Lead recov-
eries at digestion temperatures between 40°C and 120°C aver-
aged 98 4% (N = 8). Calcium was measured in the digestion
mixture by a modification of the technique of Hansen [18]. To
overcome the problem of chemical interference due to the
presence of high concentrations of salts in the digestion liquid,
0.2% lanthanum oxide was added. Recoveries of added calcium
averaged 97 3% (N = 12). Direct and standard-additions
procedures yielded equivalent results for lead as well as for
calcium. All data is expressed as JLg/g (lead) or mg/g (calcium)
wet weight.
Bone histomorphometry
As part of the prior study of aluminum-induced bone disease,
histomorphometric measurements were available in one third of
the transiliac biopsies. Quantitative histomorphometry of
trabecular bone was determined as previously described [19]
and included: volume density of trabecular bone (V%), volume
density of osteoid (Y0%), the ratio of V% and V0%, the
percentage of the surface of the calcified bone boundary cov-
ered by osteoid (os%), by osteoblasts (ob%), by osteoclasts
(oc%), and by Howship's lacunae (hl%) and the presence of
fibrosis.
Morphometric data available in five adult male dialysis pa-
tients with elevated transiliac lead/calèium ratios were com-
pared to that available in 18 adult male dialysis patients of
comparable ages without elevated transiliac lead/calcium ratios
(below 100 x 10—6) in order to determine if elevated bone lead
is associated with measurable differences in renal bone disease.
Statistical methods
Linear correlation coefficients were used to express the
relationships between on the one hand bone lead and bone
lead/calcium ratios, and on the other hand chelatable lead and
blood lead. The unpaired Student's t-test was used to compare
biochemical and bone histomorphometric data of dialysis pa-
tients with high and with low bone lead/calcium ratios.
The protocol was found ethically acceptable by the ad hoc
review board of the participating hospitals.
Results
Cadaver bone biopsies
The mean iliac crest lead of cadavers was 7.2 5.6 jg/g (N
8), and the mean lead/calcium ratio was 83 56 x 10—6 (N =
7). For the transiliac biopsies, the mean lead was 6.3 3.4 jsg/g
(N 8) and the mean lead/calcium ratio was 65 49 x 10-6 (N
8). For tibia! biopsies the mean lead was 19.9 3.7 g/g (N
= 8) and the mean lead/calcium ratio was 117 32 x 10—6 (N
8). While tibia! lead was significantly higher than iliac lead,
the tibia! and iliac leadkalcium ratios were not significantly
different (Fig. 1). In order to make the above data comparable,
only those cadavers who had undergone biopsies at the three
sites have been considered. The linear correlation coefficients
for paired measurements tended to be higher for the
lead/calcium ratios than for lead (Table 1). Transiliac bone
biopsies showed a highly significant correlation between bone
lead and the lead/calcium ratios In the dialysis population (N =
153; Fig. 2).
EDTA tests and transiliac biopsies
In 35 at risk patients (Methods) both EDTA lead mobilization
tests and transiliac bone biopsies were performed. In the lead
workers (Table 2) the mean chelatable lead was 1923 1095 pg(N = 22), bone lead was 30.1 13.8 pg/g (N = 22) and the bone
lead/ca1cim ratio was 285 179 X 10—6 (N 12). In all other
patients except three, chelatable lead was below 600 g, bone
lead was below 7 jg/g, and the bone lead/calcium ratio was
below 70 x 10_6. The linear correlation coefficients for chelat-
able lead versus bone lead (N = 35) and the bone lead/calcium
ratio (N = 22) were 0.87 and 0.83, respectively (Fig. 3). The
linear correlation coefficients for bone lead versus blood lead
V'1,C0
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Fig. 1. Lead in cadaveric bones. Comparison of lead (i) and
lead!calcium ratios (0) in iliac crest, transiliac and tibial biopsies from
cadavers. The data from non-dialysis and dialysis cadavers were pooled
since there was no systematic difference between these groups. The
data are expressed as mean SD (N = 8). Tibial lead was significantly
higher than iliac (iliac crest and transiliac) lead (P < 0.001).
Lead/calcium ratios from the three sites were not significantly different.
(N = 32) and for lead/calcium ratio versus blood lead (N = 17)
in the at risk patients were 0.88 and 0.92, respectively (Fig. 4).
Seventeen out of 21 of the patients with blood lead levels in
excess of 250 pg/liter had recent occupational exposure.
Transiliac biopsies in dialysis patients
Transiliac bone biopsies from 153 dialysis patients revealed a
non-gaussian distribution for lead (Fig. 5A) and the lead!-
calcium ratios (Fig. SB). Calcium concentrations, however,
showed a gaussian distribution (Fig. SC) indicating that lead is
the cause of the non-gaussian distribution of the bone lead and
leadlcalcium ratios.
The mean bone lead was 5.5 4.6 pg/g (median 4.2) and the
mean bone lead/calcium ratio was 53 49 x 10 (median 40)
for the 153 dialysis patients (Table 2).
Ninety-five percent of 153 dialysis patients had transiliac
bone lead less than 14 g/g and lead/calcium ratio less than 130
x 10. Attempts to trace the eight patients (4 Belgian, 2
German and 2 French) with elevated bone lead/calcium ratios to
find out if previous exposure to lead could be determined were
successful in six cases. Of these six, five reported occupational
exposure and one reported a lead-contaminated water supply.
In all cases no other cause of renal disease could be clearly
identified. Among 10 Belgian patients with a documented his-
tory of analgesic nephropathy (medical history of important
analgesic abuse, objective evidence of papillary necrosis and no
history of lead exposure), bone lead ranged from 1.1 to 6.5 sg/g,
and lead/calcium ratio ranged from 14 to 76 X lO_6. Since
uniform criteria for other renal diagnoses were not used in the
multiple participating institutions, correlations between bone
lead and other diagnoses were not attempted.
There was no correlation between aluminum and lead con-
centrations in the transiliac specimens (Spearman rank corre-
lation coefficient = 0.04), supporting the view that the dialysis
population was randomly selected with respect to lead. Further-
more, the independence of transiliac lead and aluminum levels
suggests that the bone metabolism of these elements is unre-
lated.
Transiliac bone histomorphometry available in five of the
eight patients with bone lead/calcium ratios greater than 130 x
10—6 was not significantly different from that in 18 adult dialysis
patients of the same sex (male) and mean age, except for one
measure of osteoid (os%) (Table 3). Os% was closer to refer-
ence values in the high bone lead group. The other measure of
osteoid (V0) was not significantly different between the high
and the low bone lead groups. Neither serum biochemical
parameters related to bone metabolism, nor bone aluminum
levels were significantly different between the two groups.
Discussion
Several lines of evidence support the view that transiliac
bone lead greater than 14 pg/g and bone lead/calcium ratios
greater than 130 x 106 indicate excessive past lead exposure.
The conclusion that values above these thresholds corre-
spond with excessive previous lead exposure is supported by
the observation that 21 known lead workers showed transiliac
bone leads and lead/calcium ratios above these limits, while
deceased patients with no history of renal disease or lead
exposure were well below these reference values.
The present data suggest that in the absence of lead exposure,
renal failure per se does not increase bone lead. In fact the
transiliac bone leads and lead/calcium ratios of dialysis patients
with a clearly identified etiology and no history of lead exposure
(analgesic nephropathy) were in the same range as those from
deceased subjects with normal renal function and without
documented lead exposure. It is pertinent to mention that
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Table 1. Reliability of paired cadaver bone biopsy measurements
Linear
Number of correlation
Number of duplicate coefficient
subjects values r
L-R iliac crest lead 7 — 0.98
L-R iliac crest lead/ 7 — 0.97
calcium ratio
L-R transiliac lead l2 — 0.82
L-R transiliac lead/calcium 12 — 0.97
ratio
L-R tibia lead 7 — 0.52
L-R tibia lead/calcium 7 — 0.75
ratio
Duplicate" iliac crest lead — 14 0.91
Duplicate" iliac crest lead! — 12 0.96
calcium ratio
Duplicate" transiliac lead — 24 0.94
Duplicate" transiliac lead! — 23 0.98
calcium ratio
50
Iliac Trans- Tibia
crest iliac
a Including one dialysis patient with a history of lead exposureb Adjacent biopsies
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Fig. 2. Bone lead and bone lead/calcium
ratio. Relation between the absolute bone lead
concentration and the lead/calcium ratio in
dialysis patients (N = 153). Four additional
points (absolute lead of 10.4, 28.2, 34.0 and
14.8 fsg/g; lead/calcium ratio of 200, 455, 186
14 16 18 20 and 272 x 10—6, respectively) are not shownin the figure, but they are used in the
calculations. Y = 8.91 X + 4.30, r = 0.83.
lead stores. The exact role of lead in the development of renal
failure remains to be determined.
The question can be raised whether elevated bone lead
causes bone disease which iii turn can be the reason for
excessive chelation of the stored lead. Bone histomorphometry
in dialysis patients with high bone lead showed bone lesions
similar to those encountered in matched dialysis patients with
low bone lead, suggesting elevated bone lead storage results
from exposure rather than from unusual bone metabolism.
Recent reports stated that iPTH is increased in analgesic
nephropathy as well as in renal failure with lead exposure [61,
although contrary findings have also been reported [21]. In the
present study no significant difference in iPTH level was found
between dialysis patients with high and with low transiiac bone
lead. The absence of biochemical and histomorphometric dif-
ferences between dialysis patients with low and high bone lead
suggests no systematic difference in bone pathology and metab-
olism in these patients. Furthermore, the high correlation
between chelatable lead and bone lead or lead/calcium ratio
found in the at risk patients suggests that disproportional
chelatable lead results from bone lead storage.
The study of cadaveric bone provides reference values for
iliac lead and permits the comparison of iliac with tibial values.
It appears that the tibia contains a higherabsolute concentra-
tion of lead than the ilium. This finding confirms the non-
uniform distribution of lead throughout the skeleton reported
previously [14] and indicates that in vivo measurement of bone
lead (such as by x-ray induced x-ray fluorescence) should be
performed on the tibia [7, 22, 23]. The mean tibial lead in eight
cadavers of 19.9 gg/g reported here is comparable with earlier
studies. Indeed, it is similar to the means of 23.2 g/g in 58
Englishmen [9], 14.1 pg/g in 45 Americans [24] and 18.6 tg/g in
10 Japanese [25] in postmortem analyses of non-exposed adult
males using the spectrophotometric dithizone method. The iliac
160
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Table 2. Mean transiliac bone lead and bone lead/calcium ratio
(mean 5D)
S.
2 4 6 8 10 12
Lead/
Group N Lead gg/g calcium
ratio x l0
Dialysis 153 5.5 4.6 53 49
Dialysis (top 5%) 8 20.6 2.7 190 42
Dialysis due to analgesic 10 3.7 2.1 39 19
nephropathy
Cadavers without lead 11 6.3 1.1 65 19
exposure
Lead workers 22 30.1 13.8 285 l7
a Measured in 12 lead workers
biliary excretion has been suggested as an important mecha-
nism of lead elimination [20].
The distribution of both the transiliac lead and the transiliac
lead/calcium ratio showed a small number of outliers above the
proposed limits. However the distribution of the lower values,
representing the majority (95%) of the 153 unselected dialysis
patients, showed a Gaussian profile. The values in this latter
group were comparable to those found in deceased patients
with no history of renal disease and no known lead exposure.
Furthermore, the available histories of the outliers all showed
excessive lead exposure (occupational or environmental).
In view of all these considerations it is unlikely that the
occurrence of the outllers is the consequence of renal failure,
rather they suggest that lead accumulation in these patients has
preceeded renal failure. It is well documented that only a small
fraction of those with excessive lead stores eventually develop
clinical renal failure [1, 8] and it is not yet possible to predict
which individuals will follow a progressive downhill course.
Furthermore, the question remains whether lead is the direct
cause of end-stage renal failure in patients with excessive bone
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Fig. 4. Blood lead and bone lead. A. Relation between blood lead and
bone lead in 32 at risk patients, including 21 lead workers. One
additional point (blood lead of 900 .tg/Iiter, bone lead of 76 sg/g) is not
shown in the figure, but it is used in the calculations. Y = 0.07 X — 1.97,
r = 0.88. B. Relation between blood lead and bone lead/calcium ratio in
17 at risk patients, including 9 lead workers. Y = 0.70 X — 30.13, r =
0.92. Symbols are: (0) no lead worker, creatinine clearance above the
third percentile; (•) no lead worker, creatinine clearance below the
third percentile; (D) lead worker, creatinine clearance above the third
percentile; (U) lead worker, creatinine clearance below the third
percentile.
Although we did not obtain tibial biopsies from lead workers,
the roughly threefold increase in transiliac lead in these men
compared to the cadaver specimens is consistent with the
magnitude of increase in tibial lead in occupationally exposed,
compared to non-exposed men, as reported by Barry [9]. Also,
the tibial lead values of the unexposed cadavers in the present
study are about one third of the lowest tibial values estimated in
men with prolonged occupational exposure by Wielopolski and
a
ci
0
.
0
1000 2000 3000 4000 5000
B 800
600
x
E
400
—
toC0
200
Urinary lead after EDTA, p.g
Fig. 3. Chelatable lead and bone lead. A. Relation between EDTA
lead mobilization tests and transiliac bone lead in 35 at risk patients,
including 22 lead workers. Y 0.01 X + 3.54, r = 0.87. B. Relation
between EDTA lead mobilization tests and transiliac bone lead/calcium
ratio in 22 at risk patients, including 12 lead workers. Y = 0.09 X +
42.3, r = 0.83. Lead chelate excretion was obtained over one day in
patients with normal renal function and over three days in patients with
renal failure. Symbols are: (0) no lead worker, creatinine clearance
above the third percentile; (•) no lead worker, creatinine clearance
below the third percentile; (D) lead worker, creatinine clearance above
the third percentile; (U) lead worker, creatinine clearance below the
third percentile.
crest lead of our cadavers was, however, considerably higher
than the median of 1.4 jsglg dry weight found by Grandjean in 16
autopsies in Denmark using atomic absorption spectrometry
[26].
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Table 3. Transiliac bone histomorphometry in chronic dialysis patients with high and low transiliac leada
Low transiiac bone lead
High transiliac bone lead
transiliac lead/calcium ratio
transiliac lead/calcium
ratio < 100 x 10—6 or Reference
> 130 x 10—6 transiliac lead < 10 pg/g P valuest) values [19]
Number of patients 5 18
Sex M M
Ageyears 50±15 46±11 NS
Calcium mg/dl 9.2 0.8 8.8 1.0 NS
Phosphate mg/dl 5.3 1.4 6.2 1.5 NS
Alkaline phosphatase 161 130 168 80 NS
U/liter
iPTW 4.5 1.7 5.0 3.8 NS
Transiliac bone lead sg/g 17.5 7.2 5.3 2.6 <0.01
Transiiac lead/calcium 211 139 - 50 25 <0.01
ratio" x 106
Transiiac aluminum level 49 56 30 27 NS
pg/g
V, % 20.8 6.8 19.0 5.7 NS 20.3 4.4
V.,0 % 10.3 12.3 10.7 12.9 NS 0.51 0.36
V/V,0. 5.6 6.8 4.6 5.7 NS 2.5 1.8
os % 19 13 33 16 0.05 <P < 0.1 12.5 5.3
ob % 6.7 10.7 8.9 7.7 NS 5.0 4.0
oc % 2.5 2.9 3.9 2.9 NS 0.6 0.4
hi % 7.6 4.8 7.0 5.1 NS 7.5 4.3
a All values are given as mean Snb NS corresponds toP > 0.1
iPTH levels are expressed as the ratios of the patient's values and the upper normal limits, since different radioimmunoassay kits were useddAvailable in 13 of the 18 patients with low bone lead
colleagues [27] and the minimal value found in skull bone (50
g/g) of Australian patients with lead nephropathy [10, 14].
The study of cadaveric bones demonstrated the usefulness of
the lead/calcium ratio in comparing lead contents of different
bone biopsy specimens. In addition to being more reproducible
in bone biopsies, the lead/calcium ratio compensates for
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Fig. 5. Distribution of bone lead, lead/calcium ratios, and calcium in
dialysis patients (N = 153). A. Bone lead (Mg/g). B. Bone lead/calcium
ratio X l0. C. Bone calcium (mg/g).
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demineralization which occurs during the course of renal fail-
ure.
These data reinforce the diagnostic value of the EDTA test
and make it possible to use bone biopsies in cases where the
EDTA test cannot be performed (dialysis patients). Iliac (that
is, iliac crest or transiliac) lead greater than 14 tg/g or iliac
lead/calcium ratios greater than 130 x 10—6 are equivalent to
chelatable lead in excess of 1000 g and fall in the upper fifth
percentile of European dialysis patients.
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